Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma

Tasaki, Yoshihiko; Hamamoto, Shuzo; Sugiyama, Yosuke; Tomiyama, Nami; Naiki, Taku; Etani, Toshiki; Taguchi, Kazumi; Matsuyama, Nayuka; Sue, Yasuhito; Mimura, Yoshihisa; Kubota, Hirokazu; Noda, Yusuke; Aoki, Maria; Moritoki, Yoshinobu; Nozaki, Satoshi; Kurokawa, Satoshi; Okada, Atsushi; Kawai, Noriyasu; Yasui, Takahiro; Kimura, Kazunori

doi:10.1111/iju.15220

Cited by 8 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( 17 ), elevated eosinophils prior to treatment have recently been shown to be a predictor of immune-related adverse events in several cancers treated with different ICIs ( 14 ). Similarly, in a recent cohort of patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab, an elevated eosinophil level 2 weeks after treatment may be an effective biomarker for ≥grade 2 irAEs ( 63 ).…”

Section: Discussionmentioning

confidence: 99%

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Brand,

Hunger,

Seyed Jafari

2024

Front. Oncol.

View full text Add to dashboard Cite

The importance of eosinophilic granulocytes in cancer has been widely discussed in recent years. The current study reviews the evidence on the role of eosinophilic granulocytes in melanoma as a prognostic marker for cancer progression and the efficacy of treatment with modern immune checkpoint inhibitors. A total of 33 human clinical studies were included in the review, with heterogeneous data due to differences in patients populations, study design and inclusion of small study groups. However, 28 of the 33 studies suggested that eosinophilic granulocytes could be used as a prognostic biomarker for outcome and/or potential response to systemic treatment and/or occurrence of adverse events in melanoma patients. Nevertheless, the exact role of eosinophils remains to be elucidated. Further prospective, larger and better controlled studies are warranted to clarify the significance of eosinophilic granulocytes in patients with melanoma, in more details.

show abstract

Section: Discussionmentioning

confidence: 99%

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Brand,

Hunger,

Seyed Jafari

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Furthermore, no biomarkers are available for clinical use. Previously, we investigated biomarkers that could predict the effectiveness of IO therapy [ 26 , 27 , 28 ]. In the current study, the IMDC risk may have been associated with efficacy, as in our previous study [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma

Hamamoto,

Tasaki,

Morikawa

et al. 2024

JCM

Self Cite

View full text Add to dashboard Cite

Background/Objectives: Immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) combination therapy is an essential first-line therapy for advanced renal cell carcinoma (RCC). However, reports of its efficacy and safety as late-line therapy are lacking. This study aimed to examine the efficacy and safety of IO+TKI combination therapy as a late-line therapy for patients with RCC. Methods: We retrospectively examined 17 patients with RCC who received IO+TKI combination therapy as a second-line therapy or beyond (pembrolizumab plus axitinib, n = 10; avelumab plus axitinib, n = 5; nivolumab plus cabozantinib, n = 2). Results: The overall response and disease control rates of IO+TKI combination therapy were 29.4% and 64.7%, respectively. The median overall survival was not attained. Progression-free survival was 552 days, and 94.1% of patients (n = 16) experienced adverse effects (AEs) of any grade; moreover, 41.2% of patients (n = 7) experienced grade ≥ 3 immuno-related AEs. Conclusions: IO+TKI combination therapy may be a late-line therapy option for RCC.

show abstract

“… 16 , 17 , 18 , 19 , 20 Our previous study showed that increased eosinophil proportion of ≥3.0% is an effective biomarker for predicting irAE occurrences in patients with renal cell carcinoma who received anti‐CTLA‐4 plus anti‐PD‐1 combination therapy. 21 In this study, we retrospectively investigated whether the proportion of eosinophils in patients with various cancers treated with different ICIs is a predictor of irAE occurrences.…”

Section: Introductionmentioning

confidence: 99%

Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study

Tasaki,

Sugiyama,

Hamamoto

et al. 2023

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) can cause severe immune‐related adverse events (irAEs). However, biomarkers for irAEs common to different types of ICIs and cancers have not been reported. This study examined whether eosinophils can be used as a predictor of irAEs.MethodsSix hundred fourteen patients with cancer (esophageal, gastric, head and neck, lung, melanoma, renal cell, urothelial, and other cancer) received anti‐PD‐1, anti‐PD‐L1, or anti‐CTLA‐4 plus anti‐PD‐1 therapy. The patients were divided into two groups depending on whether they experienced irAEs (irAE group) or not (non‐irAE group). Eosinophils were examined before the two‐course treatment.ResultsPatients in the irAE group who received anti‐PD‐1 or anti‐CTLA‐4 plus anti‐PD‐1 therapy had higher eosinophils before the two‐course treatment than those in the non‐irAE group (p < 0.05). The eosinophils in the anti‐PD‐L1 therapy group tended to increase in the irAE group. Furthermore, eosinophils in gastric, head and neck, lung, melanoma, renal, and urothelial cancers were significantly higher in the irAE group than in the non‐irAE group (p < 0.05). The optimal cutoff value for eosinophils against irAEs was 3.0% (area under the curve = 0.668). In multivariate analyses, eosinophils of ≥3.0% were an independent factor for irAEs (odds ratio: 2.57, 95% CI: 1.79–3.67).ConclusionAn increased eosinophil before the two‐course treatment may be a predictor of irAEs in various cancers treated with different ICIs.

show abstract

Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma

Cited by 8 publications

References 31 publications

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma

Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study

Contact Info

Product

Resources

About